PDCD1 and cancer: Since the discovery of immune checkpoint proteins, the development of antibodies against programmed cell death receptor-1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1) has aroused special interest in the treatment of some cancer cases [35, 36].